Kuros Biosciences (XSWX:KURN) Long-Term Capital Lease Obligation : CHF1.57 Mil (As of Dec. 2023)

View and export this data going back to 2002. Start your Free Trial

What is Kuros Biosciences Long-Term Capital Lease Obligation?

Kuros Biosciences's Long-Term Capital Lease Obligation for the quarter that ended in Dec. 2023 was CHF1.57 Mil.

Kuros Biosciences's quarterly Long-Term Capital Lease Obligation increased from Dec. 2022 (CHF1.50 Mil) to Jun. 2023 (CHF2.29 Mil) but then declined from Jun. 2023 (CHF2.29 Mil) to Dec. 2023 (CHF1.57 Mil).

Kuros Biosciences's annual Long-Term Capital Lease Obligation declined from Dec. 2021 (CHF1.83 Mil) to Dec. 2022 (CHF1.50 Mil) but then increased from Dec. 2022 (CHF1.50 Mil) to Dec. 2023 (CHF1.57 Mil).

Kuros Biosciences Long-Term Capital Lease Obligation Historical Data

The historical data trend for Kuros Biosciences's Long-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kuros Biosciences Long-Term Capital Lease Obligation Chart

Kuros Biosciences Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Long-Term Capital Lease Obligation

Get a 7-Day Free Trial

2.14

2.06

1.83

1.50

1.57

Kuros Biosciences Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Long-Term Capital Lease Obligation	Get a 7-Day Free Trial															1.83	1.63	1.50	2.29	1.57

Kuros Biosciences (XSWX:KURN) Long-Term Capital Lease Obligation Explanation

Long-Term Capital Lease Obligation are the amount due for long-term asset lease agreements that are nearly equivalent to asset purchases. Capital lease obligations are installment payments that constitute a payment of principal plus interest for the capital lease. The Short-Term Capital Lease Obligation is the portion of a Long-Term Capital Lease Obligation that is due over the next year.

Under US Generally Accepted Accounting Principles (GAAP), a capital lease is essentially equivalent to a purchase by the lessee if it meets the following criteria:

1. Ownership of the asset is transferred to the lessee at the end of the lease term;
2. The lease contains a bargain purchase option to buy the equipment at less than fair market value;
3. The lease term equals or exceeds 75% of the asset's estimated useful life;
4. The present value of the lease payments equals or exceeds 90% of the total original cost of the equipment.

Kuros Biosciences Long-Term Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Kuros Biosciences's Long-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

Kuros Biosciences (XSWX:KURN) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Kuros Biosciences Ltd (XSWX:KURN) » Definitions » Long-Term Capital Lease Obligation

Comparable Companies

Traded in Other Exchanges

CSBTF:USA KURNz:UK

Address

Wagistrasse 25, Schlieren, Zurich, CHE, 8952

Website

https://www.kurosbio.com

Kuros Biosciences Ltd is a Swiss-based biopharmaceutical company focused on the development of innovative products for tissue repair and bone regeneration. It operates through the following segments: Medical devices, Pharmaceuticals and Legacy portfolio. The Medical devices segment includes products such as MagnetOs and Attrax. The Pharmaceuticals segment includes products such as Fibrin-PTH, a drug-biologic combination that promotes targeted and controlled bone formation through the induction of osteoprogenitor cell differentiation, enhancement, of osteoblast proliferation and increasing the lifespan of bone-forming cells. The Legacy portfolio segment includes all other products that do not belong to the group's core business strategy.

Kuros Biosciences (XSWX:KURN) Headlines

No Headlines